/   Home   /   Newsroom   /   Research News

Scientists Find New Therapeutic Strategy for Hepatocellular Carcinoma

May 19, 2016     Email"> PrintText Size

Survivin has been considered as a key oncogene in liver carcinogenesis. However, due to the small molecular size, it is so far unsuccessful in developing inhibitors against Survivin. A comprehensive understanding of molecular mechanisms controlled by Survivin may lead to developing novel anti-HCC strategy by targeting its downstream pathways.

Hepatocellular carcinoma (HCC) is a dreaded disease worldwide lacking effective therapies. Recently, a new therapeutic strategy for this disease has been raised by Chinese researchers. In a study, Prof. HUI Lijian’s lab at Institute of Biochemistry and Cell Biology (SIBCB), Shanghai Institutes for Biological Sciences (SIBS) of Chinese Academy of Sciences and co-workers, revealed that inhibitor of apoptosis protein, Survivin, played important roles in HCC development. This work has been published in Hepatology. 

In previous studies, Prof. HUI Lijian’s lab found that Survivin played important roles for the survival of HCC initiating cells (Min, et al, Nature Cell Biology, 2012) and inducible ablation of Survivin in adult liver does not affect liver homeostasis during a long life period (Li, et al, Hepatology, 2013). These data support the notion that Survivin is an ideal target for HCC therapy.

In this study, researchers found that Survivin ablation dramatically suppresses human and mouse HCCs by triggering senescence-associated Tumor Necrosis Factor α (TNFα) and sensitizing HCC cells to TNFα-induced cell death. Combined use of mitotic inhibitor and SMAC mimetic can induce senescence-associated TNFα, enhance TNFα-induced cell death and synergistically eliminate HCC.

They found a near-complete HCC regression upon genetic deletion of Survivin in HCCs. Thorough characterization of Survivin downstream mechanisms led to an unexpected finding of a TNFα-mediated synergistic lethal effect between senescence and apoptosis sensitization on eliminating both senescent and non-senescent HCC cells. Survivin deficiency induces mitosis defect-caused senescence and increases TNFα in HCCs. Moreover, Survivin deletion hypersensitizes both senescent and neighboring non-senescent HCC cells to TNFα-triggered cell death.

Based on these findings, researchers designed and validated a new HCC therapeutic strategy by combination use of mitotic inhibitor and SMAC mimetic to induce mitosis arrest-associated senescence and to enhance TNFα-induced cell death, respectively.

This work was supported by grants from the Ministry of Science and Technology of China, National Natural Science Foundation of China project, Science and Technology Commission of Shanghai Municipality.


(Editor: LIU Jia)

Related Articles

cancer virus;hepatocellular carcinoma;HCC;liver cancer

Chinese Scientists Give Big Boost to Cancer-killing Virus

Aug 25, 2017

Chinese scientists have found a compound that helped a tumor-targeting virus kill liver cancer more effectively while sparing healthy cells, offering new hope for treating the world's second most common cancer killer, according to a study published Wednesday.

cancer stem cell;hepatocellular carcinoma;Notch2

C8orf4 Negatively Regulates Self-renewal of Liver Cancer Stem Cells

May 20, 2015

Hepatocellular carcinoma (HCC), the most common liver cancer, is the third leading cause of cancer related death. To search for driver genes in the oncogenesis of HCC and self-renewal maintenance of liver cancer stem cells, researchers from FAN Zusen's lab at the Institut...

Contact Us

Copyright © 2002 - Chinese Academy of Sciences